JDRF and Gubra collaborate on the advancement of a new glucose-responsive insulin for diabetes

JDRF has joined forces with Danish biotech company, Gubra, to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-dependent diabetes. The Gubra approach is based on a long-standing goal of researchers in the field to create a form of insulin that could linger in the bloodstream and become active only when needed.

People with type 1 diabetes (T1D) must check their blood glucose several times a day and rely on insulin injections to keep their blood sugar levels within a healthy range. Gubra’s GRI product is designed to work when blood glucose levels rise too high and to be inactive when they are in or below the standard value. The unique approach combines properties of bolus insulin (insulin that controls glucose levels at meal times) with those of a long-acting basal insulin (insulin that controls blood glucose levels during periods of fasting) to provide not only improved overall blood glucose control, but also a safer and simpler drug for people with T1D. This GRI can therefore respond to fluctuations in blood glucose levels after eating more rapidly and naturally than conventional fast-acting insulins without the risk of hypoglycemia (low blood sugar).

“JDRF is excited to partner with Gubra on developing a novel glucose-responsive insulin, which has the potential to disrupt insulin-based treatments and reduce late stage T1D complications,” says JDRF scientist,
Dr. Jonathan Rosen.

JDRF’s funding commitment will help advance Gubra’s new insulin product towards clinical and pharmaceutical development.

For more informative articles on health and type 1 diabetes news visit the Research News section on our website.

Stay connected on the latest